Documenting Medication Changes During Psychiatric Reviews: A Structured Approach

Why Structured Medication Documentation Matters

The Australian and New Zealand College of Psychiatrists (RANZCP) clinical practice guidelines emphasise that medication decisions should be evidence-based, collaboratively made, and clearly documented. AHPRA investigations consistently highlight documentation quality as a key factor in determining whether a practitioner met the expected standard of care.

Several specific risks arise from inadequate medication documentation:

• Medico-legal exposure. Without documented reasoning, a medication decision that leads to harm may appear negligent even if it was clinically sound at the time.
• Continuity of care failures. When a patient presents to an emergency department or another psychiatrist, incomplete medication records can lead to dangerous prescribing decisions.
• Medicare audit risk. MBS item 291 and 296 consultations require evidence of the clinical content that justified the billing. Medication management is often the core clinical activity.
• Pharmacy and dispensing errors. Clear documentation of intended doses, schedules, and monitoring requirements reduces the risk of dispensing errors when scripts are written.

A Structured Framework for Medication Documentation

Every medication change documented during a psychiatric review should address six core elements. This framework applies whether you are starting a new medication, adjusting a dose, switching agents, or ceasing treatment.

1. Current Medication List with Doses and Adherence

Begin every review note with the current medication list, including doses, frequency, and the patient's reported adherence. This provides the baseline against which any changes are measured.

Document any discrepancies between the prescribed regimen and what the patient is actually taking. Non-adherence should be explored non-judgementally and the reasons recorded — whether financial, side effect-related, or driven by the patient's beliefs about medication.

2. Clinical Reasoning for the Change

This is the most frequently omitted element and the most legally important. Document why you are making the change. What symptoms have not responded? What evidence supports the change you are making? What alternatives were considered and why they were rejected?

Reference relevant guidelines where applicable. For example: 'Consistent with RANZCP guidelines for treatment-resistant depression, augmentation with lithium is recommended after failure of two adequate antidepressant trials.'

3. Side Effect Assessment

Document a structured side effect inquiry. This should cover common side effects relevant to the medication class, as well as any side effects the patient is spontaneously reporting.

For antipsychotics, this means metabolic monitoring (weight, waist circumference, blood glucose, lipids). For lithium, it means renal function, thyroid function, and toxicity symptoms. For SSRIs, it includes sexual dysfunction, gastrointestinal symptoms, and bleeding risk in older patients.

4. Monitoring Requirements

Specify what investigations are required, when they should be performed, and what you are looking for. This includes pathology (bloods, ECG where relevant), clinical observations (weight, blood pressure), and rating scale assessments.

Document clearly whether pathology has been ordered and when results are expected. If the patient is overdue for monitoring, document this and what action you have taken.

5. Patient and Carer Understanding and Consent

Record that the patient (and where relevant, their carer or family) has been informed about the medication change, the expected benefits, potential side effects, and the monitoring plan. Document any questions they raised and your responses.

This does not require a formal written consent process for routine medication changes, but it does require evidence in the notes that the discussion occurred and the patient was an informed participant in the decision.

6. Follow-Up Plan

Document the planned follow-up interval, what you will be assessing at the next review, and any triggers that should prompt earlier contact (such as worsening symptoms, emergence of side effects, or suicidal ideation).

Scenario 1: Starting an SSRI for Major Depression

Clinical context: A 34-year-old female presenting for an initial psychiatric consultation. Referred by GP for moderate-to-severe major depressive episode. PHQ-9 score 18. No previous psychiatric medication trials. No significant medical history.

Medication documentation:

Current medications: Nil regular. Occasional paracetamol for headaches. No herbal or over-the-counter supplements.

Clinical reasoning for change: Patient presents with a moderate-to-severe major depressive episode meeting DSM-5 criteria. Symptoms include persistent low mood, anhedonia, insomnia (both initial and middle), poor concentration, reduced appetite with 4kg weight loss over three months, and passive suicidal ideation without plan or intent. PHQ-9 score 18 (moderately severe). Given severity, pharmacotherapy is indicated alongside psychological intervention. Commenced sertraline 50mg daily as first-line SSRI with strong evidence base for MDD. Sertraline selected over other SSRIs due to favourable side effect profile and safety in the event of future pregnancy (patient expressed desire to conceive within the next two years).

Side effects discussed: Nausea (usually transient, take with food), headache, initial anxiety/agitation (may worsen in first 1-2 weeks), sexual dysfunction, serotonin syndrome (rare, advised not to combine with St John's Wort or other serotonergic agents). Discussed black box warning regarding suicidal ideation in young adults and advised patient to present to ED if active suicidal thoughts develop.

Monitoring: Review in two weeks to assess early response and tolerability. If well tolerated, increase to 100mg at two-week review. Pathology: baseline FBC, UEC, LFTs, TFTs ordered (fasting, for completeness before initiating treatment). PHQ-9 to be repeated at each review.

Patient understanding: Patient expressed understanding of the expected timeline for response (2-4 weeks for initial improvement, 6-8 weeks for full effect). Agreed to the monitoring plan. Partner present during discussion and supportive of commencing treatment.

Follow-up: Review in two weeks. Advised to contact rooms or present to ED if significant worsening occurs before that time.

Scenario 2: Cross-Tapering Antipsychotics

Clinical context: A 45-year-old male with schizophrenia, currently on olanzapine 20mg nocte. Metabolic syndrome has developed: BMI 38, HbA1c 6.4% (pre-diabetic), triglycerides elevated. Switching to aripiprazole.

Medication documentation:

Current medications: Olanzapine 20mg nocte. Metformin 500mg BD (commenced by GP for metabolic syndrome). Atorvastatin 20mg nocte.

Clinical reasoning for change: Patient has been psychiatrically stable on olanzapine 20mg for 18 months with no psychotic symptoms. However, significant metabolic complications have developed: BMI increased from 29 to 38 since olanzapine initiation, HbA1c 6.4% (pre-diabetic), and triglycerides 3.2 mmol/L despite atorvastatin. Consistent with RANZCP guidelines on metabolic monitoring and NICE CG178 recommendations, switching to a metabolically neutral antipsychotic is indicated. Aripiprazole selected due to lower metabolic risk and evidence base for maintenance treatment in schizophrenia. Cross-taper approach chosen over abrupt switch to reduce relapse risk.

Cross-taper plan: Week 1-2: Commence aripiprazole 10mg mane, continue olanzapine 20mg nocte. Week 3-4: Increase aripiprazole to 15mg mane, reduce olanzapine to 10mg nocte. Week 5-6: Increase aripiprazole to 20mg mane if tolerated, cease olanzapine. Adjust timeline based on tolerability and mental state.

Side effects discussed: Aripiprazole may cause akathisia (restlessness), insomnia, nausea. Discussed that olanzapine reduction may temporarily affect sleep and appetite. Discussed risk of relapse during cross-taper and early warning signs to monitor.

Monitoring: Fortnightly psychiatry reviews during cross-taper. Fasting glucose, lipids, weight, and waist circumference at baseline, 6 weeks, and 12 weeks post-switch. Mental state assessment at each review with early warning sign monitoring.

Patient understanding: Patient and his sister (primary support) understand the rationale for switching and the cross-taper process. Written schedule of dose changes provided. Patient has early warning sign relapse prevention plan in place. Sister has contact details for crisis team.

Follow-up: Review in two weeks. Crisis plan in place with CATT team contact details.

Scenario 3: Lithium Dose Adjustment

Clinical context: A 52-year-old female with bipolar I disorder on lithium 900mg nocte. Serum lithium level at 0.5 mmol/L (subtherapeutic). Has experienced a hypomanic episode over the past fortnight.

Medication documentation:

Current medications: Lithium carbonate 900mg nocte. Lamotrigine 200mg daily. Temazepam 10mg nocte PRN (using 3-4 nights per week currently).

Clinical reasoning for change: Lithium level 0.5 mmol/L on current dose of 900mg nocte is subtherapeutic for acute mood stabilisation (target range 0.6-0.8 mmol/L for maintenance, 0.8-1.0 mmol/L for acute episodes). Patient presenting with features of hypomania over the past two weeks: reduced sleep (4-5 hours per night without fatigue), increased goal-directed activity, rapid speech, increased spending (approximately $3,000 on online purchases). Not yet meeting criteria for a full manic episode but trajectory is concerning. Increased lithium to 1200mg nocte to target serum level of 0.8-1.0 mmol/L given emerging mood episode.

Side effects assessment: No current tremor, no gastrointestinal symptoms, no polyuria or polydipsia. Weight stable. No signs of lithium toxicity. Renal function stable (eGFR 78, creatinine 72). TSH mildly elevated at 4.8 mIU/L (previous 3.2) — to be monitored closely with dose increase.

Monitoring: Serum lithium level in 5-7 days (steady state after dose increase). Repeat UEC and TFTs in 4 weeks. Discussed signs of lithium toxicity: vomiting, diarrhoea, coarse tremor, confusion, unsteadiness. Advised to maintain adequate hydration, avoid dehydration, and present to ED if toxicity symptoms develop. Advised to hold lithium dose if vomiting or diarrhoea occurs and contact rooms.

Patient understanding: Patient understands the dose increase and the rationale. Discussed importance of hydration and maintaining regular meals. Discussed avoiding NSAIDs (patient uses ibuprofen occasionally for joint pain — advised paracetamol as alternative). Husband present and aware of toxicity signs.

Follow-up: Review in one week for lithium level result and mental state assessment. Earlier if symptoms escalate toward mania.

The Dictation Advantage for Medication Documentation

The structured framework above is comprehensive, but it takes time to write out longhand. Many psychiatrists find that medication documentation quality declines across a busy clinic day as time pressure mounts.

Dictating medication decisions immediately after each review captures the clinical reasoning while it is fresh. A 90-second dictation covering the six elements of the framework can then be structured into a formatted medication note by an AI documentation tool like Grounded Scribe, which uses clinical note templates designed for psychiatric practice.

The key advantage is that dictation captures nuance and reasoning that is often lost when a psychiatrist tries to compress notes into a few hurried lines at the end of a long day. The difference between a note that says 'increased lithium to 1200mg' and one that captures the full clinical reasoning, monitoring plan, and patient discussion is the difference between defensible and indefensible documentation.

Summary

Structured medication documentation is not optional in modern psychiatric practice. Every medication change should address the current regimen, clinical reasoning, side effects, monitoring requirements, patient understanding, and follow-up plan. Using a consistent framework ensures that nothing is missed, reduces medico-legal risk, and supports continuity of care across the healthcare system.

Start your 14-day free trial at Grounded Scribe.

Important Disclaimer

*This article is for informational purposes only and does not constitute legal, clinical, or regulatory advice. Grounded Scribe is a documentation tool — it does not provide legal guidance or ensure compliance with any specific legislative, regulatory, or registration body requirements. Practitioners are solely responsible for ensuring their documentation meets the standards of their registration board, employer, and applicable legislation. All AI-generated content must be reviewed, edited, and approved by the practitioner before it becomes part of the clinical record. For medico-legal, child protection, or tribunal documentation, always seek independent legal and professional advice relevant to your jurisdiction and specific circumstances.*